2 results
Approved WMOCompleted
Primary- To evaluate disease-related characteristics and biomarkers in patients with mycosis fungoides compared to healthy volunteers; Secondary- To evaluate the variability of the selected biomarkers between patients and within patients over time…
Approved WMORecruiting
Part 1: dose safety confirmationPrimary: To evaluate the proportion of participants with TRAEs leading to discontinuation within 12 weeks after the first dose of nivolumab plus2 different dose levels of relatlimab (360 mg and 720 mg) in combination…